If you have been reading about hexenoyl cap and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Prix Galien CEE Pro Bono Humanum Award: In November 2025, Thomsen accepted the Prix Galien CEE Pro Bono Humanum Award on behalf of the Novo Nordisk Foundation, which received the distinction for its contributions to global health initiatives and scientific research. The award was presented at the Central and Eastern Europe edition of the Prix Galien programme in Warsaw, Poland. PwC Business Executive of the Year 2025: In 2025, Thomsen received PwC Denmark's Business Executive of the Year award. The distinction is presented annually to executives in Danish business who have demonstrated notable leadership, strategic influence, and impact on society. PwC's award committee highlighted Thomsen's role in leading the Novo Nordisk Foundation and its expansion of scientific, global health and sustainability initiatives. Golden Plate Award (2024): Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. Knight of the Order of the Dannebrog: On December 12, 2022, he was appointed as a Knight of the Order of the Dannebrog by the Danish Royal House
=== Characteristics of elution mode === In elution mode, solutes are applied to the column as narrow bands and, at low concentration, move down the column as approximately Gaussian peaks. These peaks continue to broaden as they travel, in proportion to the square root of the distance traveled. For two substances to be resolved, they must migrate down the column at sufficiently different rates to overcome the effects of band spreading. Operating at high concentration, where the isotherm is curved, is disadvantageous in elution chromatography because the rate of travel then depends on concentration, causing the peaks to spread and distort. Retention in elution chromatography is usually controlled by adjusting the composition of the mobile phase (in terms of solvent composition, pH, ionic strength, and so forth) according to the type of stationary phase employed and the particular solutes to be separated. The mobile phase components generally have lower affinity for the stationary phase than do the solutes being separated, but are present at higher concentration and achieve their effects due to mass action. Resolution in elution chromatography is generally better when peaks are strongly retained, but conditions that give good resolution of early peaks lead to long run-times and excessive broadening of later peaks unless gradient elution is employed. Gradient equipment adds complexity and expense, particularly at large scale.
Many bacteria are motile (able to move themselves) and do so using a variety of mechanisms. The best studied of these are flagella, long filaments that are turned by a motor at the base to generate propeller-like movement. The bacterial flagellum is made of about 20 proteins, with approximately another 30 proteins required for its regulation and assembly. The flagellum is a rotating structure driven by a reversible motor at the base that uses the electrochemical gradient across the membrane for power.
Sources: en.wikipedia.org
== Advertising == Sonic ran its first television advertisement in 1977. One of the company's most memorable advertising campaigns, which ran from 1987 to 1993, featured Frankie Avalon. In May 1999, the company began a new campaign featuring the character Katie the Carhop. Sonic was also involved with NASCAR. The company contracted with Richard Childress Racing in late 2000 to be an associate sponsor for Dale Earnhardt Sr. during the 2001 NASCAR Winston Cup Series season. After Earnhardt died in an accident at the 2001 Daytona 500, the company continued its sponsorship with his replacement driver Kevin Harvick, through the end of the 2003 season. Sonic returned to NASCAR several years later to sponsor Sam Hornish Jr. and Richard Petty Motorsports in 2015. In 2004, the company became more widely known nationally by advertising in television markets hundreds of miles from its nearest franchise. Improvisational actors T. J. Jagodowski and Peter Grosz became known to American television viewers from their "Two Guys" series of commercials. Similar series of ads for the company have featured other duos of improvisational performers, including Molly Erdman and Brian Huskey, Katie Rich and Sayjal Joshi, and Emily Wilson and Tim Baltz. In 2010, national auditions were held and a new series of commercials began airing, some of which featured carhops from Wisconsin and Austin, Texas. In 2012 the "Two Guys" returned to the company's television ads. In 2018 Sonic supplemented their "Two Guys" commercials with complementary "Two Gals" commercials.
== Discovery == The original discovery of Substance P (SP) was in 1931 by Ulf von Euler and John H. Gaddum as a tissue extract that caused intestinal contraction in vitro. Its tissue distribution and biologic actions were further investigated over the following decades. The eleven-amino-acid structure of the peptide was determined by Chang, et al. in 1971. In 1983, Neurokinin A (previously known as substance K or neuromedin L) was isolated from porcine spinal cord and was also found to stimulate intestinal contraction.
Another former Sport Dynamo athlete, Ilona Slupianek, was disqualified for doping. (Ilona Slupianek failed a test along with three Finnish athletes at the 1977 European Cup, becoming the only East German athlete ever to be convicted of doping) Based on the admission by Pollack, the United States Olympic Committee asked for the redistribution of gold medals won in the 1976 Summer Olympics. Despite court rulings in Germany that substantiate claims of systematic doping by some East German swimmers, the IOC executive board announced that it has no intention of revising the Olympic record books. In rejecting the American petition on behalf of its women's medley relay team in Montreal and a similar petition from the British Olympic Association on behalf of Sharron Davies, the IOC made it clear that it wanted to discourage any such appeals in the future.
Sources: en.wikipedia.org
Hart (1874–1953), American biochemist at the University of Wisconsin-Madison who studied farm animal diet. Brian S. Hartley FRS (1926–2021). British biochemist at Imperial College London. Known for studies on chymotrypsin and other proteolytic enzymes. Hamilton Hartridge FRS (1886–1976). British eye physiologist known in biochemistry for the continuous-flow method for following fast reactions. Demis Hassabis (b. 1976). British computer scientist and artificial intelligence researcher at University College London. Nobel Prize in chemistry 2024. Reinhart Heinrich (1946–2006). German biophysicist at the Humboldt University of Berlin, noted for the origin and development of metabolic control analysis. Max Henius (1859–1935). Danish-American biochemist who specialized in fermentation processes. Founder of the Chicago-based American Brewing Academy. Victor Henri (1872–1940). French physical chemist of Russian parents at the University of Liège. He was the first to apply ideas of physical chemistry to the properties of enzymes. Avram Hershko (b. 1937 as Herskó Ferenc). Hungarian-Israeli biochemist at the Technion (Haifa), known for the discovery of ubiquitin-mediated protein degradation. Nobel Prize in Chemistry (2004). Foreign associate Natl. Acad. Sci. USA.
=== Activism === Kardashian supports the recognition of the Armenian genocide and has visited Tsitsernakaberd, the memorial to the victims in Yerevan, Armenia. In April 2021, Kardashian praised President Joe Biden for officially recognizing the Armenian Genocide, thus becoming the first US president to do so. In October 2020, Kardashian spoke out in support of Republic of Artsakh and Armenians, condemning Azerbaijan's involvement in the 2020 Nagorno-Karabakh conflict. On October 10, 2020, she spoke on the ArmeniaFund fundraising telethon and urged viewers to donate money to help those impacted by the recent war.
== Vitamin B12 == Vitamin B12 plays an integral role in this reaction. Coenzyme B12 (adenosyl-cobalamin) is an organometallic form of vitamin B12 and serves as the cofactor of Methylmalonyl-CoA mutase, which is an essential enzyme in the human body. The transformation of Methylmalonyl-CoA to Succinyl-CoA by this enzyme is a radical reaction.
Enzyme specificity refers to the interactions between any particular enzyme and its corresponding substrate. In addition to the specificity in binding its substrates, correct proximity and orientation as well as binding the transition state provide an additional layer of enzyme specificity. Enzymes vary in the specificity of the substrates that they bind to, in order to carry out specific physiological functions. Some enzymes may need to be less specific and therefore may bind to numerous substrates to catalyze a reaction. On the other hand, certain physiological functions require extreme specificity of the enzyme for a single specific substrate in order for a proper reaction and physiological phenotype to occur. The different types of categorizations differ based on their specificity for substrates. Most generally, they are divided into four groups: absolute, group, linkage, and stereochemical specificity.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.